Patrick G. LePore has been appointed to the company's Board of Directors, effective July 1, 2017. Mr. LePore is an independent director. Since 2007, LePore served as chairman, CEO and president of Par Pharmaceuticals, Inc., until the company's acquisition by private equity investor TPG in 2012. He remained as chairman of the new company where he led the sale of the company to Endo Pharmaceuticals. LePore began his career with Hoffmann LaRoche. Later, he founded Boron LePore and Associates, a medical communications company, which he took public and was eventually sold to Cardinal Health. He is a member of the board of directors of PharMerica and Innoviva, and is a trustee of Villanova University. LePore earned his bachelor's degree from Villanova University and Master of Business Administration from Fairleigh Dickinson University.
John C. Chapman was appointed to the board of directors in 2018. Chapman is a retired audit partner for KPMG, having specialized in providing audit services to large complex multinational pharmaceutical and consumer market companies. During his tenure at KPMG, he served for six years as a member of the firm’s board of directors and for several years as KPMG’s global chair of pharmaceuticals and chemicals. Chapman also served as the global lead partner for some of KPMG’s largest clients, including Pfizer, Hoechst, and PepsiCo, among others. Chapman, a certified public accountant (CPA), earned a bachelor of business administration in accounting practice degree from Pace University, New York.
Chief Executive Officer
Timothy C. Crew was appointed chief executive officer (CEO) in January 2018. Mr. Crew most recently served as CEO of Cipla North America, a global pharmaceutical company based in Mumbai, India, from 2013 to 2017. Previously, he worked for eight years at Teva Pharmaceuticals, where he served as senior vice president and commercial operating officer of the North American Generics division, the world's largest generic operation with multiple billions of dollars of annual sales. Before that, Mr. Crew was Teva's vice president, Alliances and Business Development. From 2001 to 2004, Mr. Crew was executive vice president, North America, for Dr. Reddy's Laboratories. Crew began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development and strategic planning. Prior to his pharmaceutical roles, Mr. Crew served in the United States Army, where he rose to the rank of Captain. Mr. Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School.
David Drabik was nominated to become a board member by the Nominating Committee of the Company in November 2010 and elected to the Board by the shareholders at the Annual Shareholders Meeting on January 19, 2011. Mr. Drabik is an independent director. Since 2002, Mr. Drabik has been President of Cranbrook & Co., LLC (Cranbrook), an advisory firm primarily serving the private equity and venture capital community. At Cranbrook, Mr. Drabik assists and advises its clientele on originating, structuring, and executing private equity and venture capital transactions. From 1995 to 2002, Mr. Drabik served in various roles and positions with UBS Capital Americas (and its predecessor UBS Capital LLC), a New York City based, private equity and venture capital firm that managed $1.5 billion of capital. From 1992 to 1995, Mr. Drabik was a banker with Union Bank of Switzerlands Corporate and Institutional Banking division in New York City. Mr. Drabik graduated from the University of Michigan with a Bachelors of Business Administration degree.
Jeffrey Farber was appointed a Director of the Company in May 2006 and was appointed Chairman of the Board of Directors in July 2012. Jeffrey Farber joined the Company in August 2003 as Secretary. For the past 13 years, Mr. Farber has been President and the owner of Auburn Pharmaceutical (Auburn), a national generic pharmaceutical distributor. Prior to starting Auburn, Mr. Farber served in various positions at Major Pharmaceutical (Major), where he was employed for over 15 years. At Major, Mr. Farber was involved in sales, purchasing and eventually served as President of the mid-west division. Mr. Farber also spent time working at Majors manufacturing division Vitarine Pharmaceuticals where he served on its Board of Directors. Mr. Farber graduated from Western Michigan University with a Bachelors of Science Degree in Business Administration and participated in the Pharmacy Management Graduate Program at Long Island University. Mr. Farber is the son of William Farber, the Chairman of the Board of Directors and the principal shareholder of the Company
James M. Maher, was appointed to the Board of Directors on June 3, 2013, effective July 1, 2013. Maher spent his entire professional career with PricewaterhouseCoopers (PwC) LLP. After nearly 40 years with PwC, 30 years as a partner, he retired in June 2012. Most recently, Maher served as the managing partner of PwC’s U. S. assurance practice, comprised of more than 1,100 partners and 12,000 staff. Previously, he served as the regional assurance leader for the metro assurance practice. During his tenure at PwC, Maher worked closely with senior management at several multinational companies, dealing extensively with significant acquisitions, divestitures, initial public offerings and secondary offerings. Maher earned a bachelor’s degree in Accounting from C. W. Post Campus of Long Island University (now LIU Post).
Albert Paonessa, III, was appointed as a Director of the Company in July 2015. Mr. Paonessa retired from Anda, Inc., the fourth largest distributor of generic drugs in the U.S. in January 2015 after serving as President for the past 10 years. He previously served as Anda’s Senior Vice President of Sales and before that as Vice President of IT. Earlier, Mr. Paonessa was Vice President of Operations for VIP Pharmaceuticals, which was acquired by Anda’s parent company, Andrx, in 2000. Mr. Paonessa earned a Bachelor of Arts degree in Interpersonal Communications from Bowling Green State University.
Paul Taveira, currently serves as chief executive officer of A&D Environmental Services Inc., an environmental and industrial services company. Earlier, he was managing partner of Precision Source LLC, a manufacturer of precision parts for various industries across the United States. Previously, Mr. Taveira rose through the ranks of PSC Inc., a national provider of environmental services, most recently as its president. Before that, he held a number of senior management positions with Clean Harbors Inc., an international provider of environmental and energy services. Mr. Taveira earned a bachelors degree in biology from Worcester State University.